Marlio Charles Mosseri Acquires 240,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri bought 240,000 shares of Nuvectis Pharma stock in a transaction that occurred on Friday, February 7th. The stock was purchased at an average price of $5.00 per share, with a total value of $1,200,000.00. Following the purchase, the insider now directly owns 2,884,121 shares in the company, valued at $14,420,605. The trade was a 9.08 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Friday, December 13th, Marlio Charles Mosseri acquired 17,000 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $4.70 per share, for a total transaction of $79,900.00.

Nuvectis Pharma Stock Up 9.1 %

Nuvectis Pharma stock opened at $6.86 on Thursday. The stock has a 50-day moving average price of $5.70 and a 200 day moving average price of $6.34. The company has a market capitalization of $132.54 million, a price-to-earnings ratio of -5.91 and a beta of 0.22. Nuvectis Pharma, Inc. has a 52 week low of $4.44 and a 52 week high of $12.10.

Institutional Trading of Nuvectis Pharma

Several institutional investors and hedge funds have recently bought and sold shares of NVCT. GSA Capital Partners LLP increased its stake in shares of Nuvectis Pharma by 3.7% in the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after acquiring an additional 1,790 shares during the period. Baxter Bros Inc. boosted its holdings in Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock valued at $81,000 after purchasing an additional 2,500 shares during the last quarter. Nations Financial Group Inc. IA ADV grew its position in Nuvectis Pharma by 35.0% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock worth $73,000 after purchasing an additional 3,500 shares during the period. Forbes J M & Co. LLP raised its stake in shares of Nuvectis Pharma by 21.9% during the 4th quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock valued at $319,000 after buying an additional 10,599 shares during the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Nuvectis Pharma in the 4th quarter valued at about $135,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.